Prof.
Tadeusz Robak
Department of Hematology, Medical University of
Lodz
Copernicus Memorial Hospital, 93-510 Lodz, Ul.
Ciolkowskiego 2, Poland
Email: robaktad@csk.umed.lodz.pl
Qualifications
1993 Professor, Medical University of Lodz,
Poland
1979 Ph.D., Medical University of Lodz, Poland
1973 M.D., Medical University of Lodz, Poland
Publications
(Selected)
-
Li J, Zhi J, Wenger M, Valente N, Dmoszynska A,
Robak T, Mangat R, Joshi A, Visich J. Population Pharmacokinetics of Rituximab
in Patients With Chronic Lymphocytic Leukemia. J Clin Pharmacol. 2012 Jan 10.
-
Pluta P, Smolewski P, Pluta A, Cebula-Obrzut B,
Wierzbowska A, Nejc D, Robak T, Kordek R, Gottwald L, Piekarski J, Jeziorski A.
Significance of bax expression in breast cancer patients. Pol Przegl Chir. 2011
Oct 1; 83(10): 549-53.
-
Kantarjian HM, Shah NP, Cortes JE, Baccarani M,
Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky
C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga
E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly
diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a
randomized phase 3 trial (DASISION). Blood. 2011 Dec 9.
-
Kropff M,
Giongco-Baylon H, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin
C, Blade J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg
E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the
treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM,
a randomized trial. Haematologica. 2011 Dec 1.
-
Eichhorst B, Dreyling M, Robak T, Montserrat E,
Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2011 Sep; 22 Suppl 6: vi50-4.
-
Elter T, Gercheva-Kyuchukova L, Pylylpenko H,
Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C,
Hallek M, Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in
patients with previously treated chronic lymphocytic leukaemia: a randomised
phase 3 trial. Lancet Oncol. 2011 Dec; 12(13): 1204-13.
-
Smolewski P, Robak T. Inhibitors of Apoptosis
Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological
Malignancies. Curr Mol Med. 2011 Dec 1; 11(8): 633-49.
-
Szmigielska-Kaplon A, Robak T. Hypomethylating
agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Curr
Cancer Drug Targets. 2011 Sep 1; 11(7): 837-48.
-
Pluta P, Cebula-Obrzut B, Ehemann V, Pluta A,
Wierzbowska A, Piekarski J, Bilski A, Nejc D, Kordek R, Robak T, Smolewski P,
Jeziorski A. Correlation of Smac/DIABLO protein expression with the
clinico-pathological features of breast cancer patients. Neoplasma. 2011; 58(5): 430-5.
-
Robak T. Management of hairy cell leukemia
variant. Leuk Lymphoma. 2011 Jun; 52 Suppl 2: 53-6.
-
Crowther-Swanepoel D, Di Bernardo MC, Jamroziak
K, Karabon L, Frydecka I, Deaglio S, D'Arena G, Rossi D, Gaidano G, Olver B,
Lloyd A, Broderick P, LaurentiL, Szemraj-Rogucka Z, Robak T, Catovsky D,
Houlston RS. Common genetic ariation at 15q25.2 impacts on chronic lymphocytic
leukaemia risk. Br J Haematol. 2011 Jul; 154(2): 229-33.
-
Moreau P, Pylypenko H, Grosicki S, Karamanesht
I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B,
Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W,
Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in
patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority
study. Lancet Oncol. 2011 May; 12(5): 431-40.
Epub 2011 Apr 18. Erratum in: Lancet Oncol. 2011 Jun; 12(6): 522.
-
Bladé J, Sonneveld P, San Miguel JF, Sutherland
HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL,
Orlowski RZ; DOXIL-MMY-3001 Study Investigators. Efficacy and safety of
pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma:
effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk.
2011 Feb; 11(1): 44-9.
-
Richardson P, Schlag R, Khuageva N, Dimopoulos
M, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T,
Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde
H, San Miguel JF. Characterization of haematological parameters with
bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed
myeloma, with evaluation of long-term outcomes and risk of thromboembolic
events with use of erythropoiesis-stimulating agents: analysis of the VISTA
trial. Br J Haematol. 2011 Mar 6.
-
Kotkowska A, Wawrzyniak E, Blonski JZ, Robak T,
Korycka-Wolowiec A. Chromosomal aberrations in chronic lymphocytic leukemia
detected by conventional cytogenetics with DSP30 as a single agent: comparison
with FISH. Leuk Res. 2011 Aug; 35(8): 1032-8.
-
Robak T, Szmigielska-Kapłon A, Pluta A,
Grzybowska-Izydorczyk O, Wolska A, Czemerska M, Wierzbowska A. Novel and
emerging drugs for acute myeloid leukemia: pharmacology and therapeutic
activity. Curr Med Chem. 2011; 18(5): 638-66.
-
Lech-Maranda E, Robak E, Robak T. Novel systemic
drugs for cutaneous T-cell lymphoma. Recent Pat Anticancer Drug Discov. 2011
Jan; 6(1): 70-93.
Review.
-
Robak T, Robak E. New anti-CD20 monoclonal
antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011
Feb 1; 25(1): 13-25.
-
Robak T, Mainau C, Pyringer B, Chojnowski K,
Warzocha K, Dmoszynska A, Straub J, Imbach P. Efficacy and safety of a new
intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with
immune thrombocytopenia. Hematology. 2010 Oct; 15(5): 351-9.
-
Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G,
Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha
K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA,
Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M. Effect of
FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010 Nov 18; 116(20): 4212-22.
-
Whittaker SJ, Demierre MF, Kim EJ, Rook AH,
Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A,
McCulloch W, Kim YH. Final results from a multicenter, international, pivotal
study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010
Oct 10; 28(29): 4485-91.
-
Treliński J, Wierzbowska A, Krawczyńska A,
Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K. Plasma levels of
angiogenic factors and circulating endothelial cells in essential
thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F
mutational status. Leuk Lymphoma. 2010 Sep; 51(9): 1727-33.
-
Robak T. Hairy-cell leukemia variant: recent
view on diagnosis, biology and treatment. Cancer Treat Rev. 2011 Feb; 37(1): 3-10.
Epub 2010 Jun 16. Review.
-
Treliński J, Wierzbowska A, Krawczyńska A,
Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K. Circulating
endothelial cells in essential thrombocythemia and polycythemia vera:
correlation with JAK2-V617F mutational status, angiogenic factors and
coagulation activation markers. Int J Hematol. 2010 Jun; 91(5): 792-8.
Epub 2010 May 15.
-
Coiffier B, Losic N, Rønn BB, Lepretre S,
Pedersen LM, Gadeberg O, Frederiksen H, van Oers MH, Wooldridge J, Kloczko J,
Holowiecki J, Hellmann A, Walewski J, Robak T, Petersen J. Pharmacokinetics and
pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal
CD20 antibody, in patients with relapsed or refractory chronic lymphocytic
leukaemia: a phase 1-2 study. Br J Haematol. 2010 Jul; 150(1): 58-71.
-
Robak T, Jamroziak K, Gora-Tybor J,
Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J,
Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K,
Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.
Comparison of cladribine plus cyclophosphamide with fludarabine plus
cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a
phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3
Study). J Clin Oncol. 2010 Apr 10; 28(11): 1863-9.
-
Robak T, Dmoszynska A, Solal-Céligny P, Warzocha
K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M,
Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW,
Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and
cyclophosphamide prolongs progression-free survival compared with fludarabine
and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
J Clin Oncol. 2010 Apr 1; 28(10): 1756-65.
-
Robak T. Improving FCR immunochemotherapy in
CLL. Blood. 2010 Jan 21; 115(3): 437-8.
-
Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, Wolska
A, Szmigielska-Kaplon A, Czemerska M, Pluta P, Robak T, Smolewski P,
Wierzbowska A. Influence of high expression of Smac/DIABLO protein on the
clinical outcome in acute myeloid leukemia patients. Leuk Res. 2010 Oct; 34(10): 1308-13.
-
Grzybowska-Izydorczyk O, Cebula B, Robak T,
Smolewski P. Expression and prognostic significance of the inhibitor of
apoptosis protein (IAP) family and its antagonists in chronic lymphocytic
leukaemia. Eur J Cancer. 2010 Mar; 46(4): 800-10.
-
Robak T. Application of new drugs in chronic
lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2010 May 10; 2(2): e2010011.
-
Robak T, Robak P, Smolewski P. TRU-016, a
humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell
malignancies. Curr Opin Investig Drugs. 2009 Dec; 10(12): 1383-90.
Review.
-
Robak T, Jamroziak K, Robak P. Current and
emerging treatments for chronic lymphocytic leukaemia. Drugs. 2009; 69(17): 2415-49.
-
Plewka M, Krzemińska-Pakuła M, Lipiec P, Peruga
JZ, Jezewski T, Kidawa M, Wierzbowska-Drabik K, Korycka A, Robak T, Kasprzak
JD. Effect of intracoronary injection of mononuclear bone marrow stem cells on
left ventricular function in patients with acute myocardial infarction. Am J
Cardiol. 2009 Nov 15; 104(10): 1336-42.
Epub 2009 Sep 25.
-
Liu JM, Gora-Tybor J, Grzybowska-Izydorczyk O,
Bignon J, Robak T, Wdzieczak-Bakala J. Elevated plasma levels of the angiogenic
tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic
malignancies. Leuk Lymphoma. 2009 Dec; 50(12): 2096-7.
-
Treliński J, Tybura M, Smolewski P, Robak T,
Chojnowski K. The influence of low-dose aspirin and hydroxyurea on
platelet-leukocyte interactions in patients with essential thrombocythemia.
Blood Coagul Fibrinolysis. 2009 Dec; 20(8): 646-51.
-
Zolnierczyk JD, Błoński JZ, Robak T, Kiliańska
ZM, Wesierska-Gadek J. Roscovitine triggers apoptosis in B-cell chronic
lymphocytic leukemia cells with similar efficiency as combinations of
conventional purine analogs with cyclophosphamide. Ann N Y Acad Sci. 2009 Aug; 1171: 124-31.
-
Robak T. How to improve the treatment outcome in
chronic lymphocytic leukemia? Leuk Res. 2010 Mar; 34(3): 272-5.
-
Robak T, Salama A, Kovaleva L, Vyhovska Y,
Davies SV, Mazzucconi MG, Zenker O, Kiessling P; International Privigen in ITP
Study Group. Efficacy and safety of Privigen, a novel liquid intravenous
immunoglobulin formulation, in adolescent and adult patients with chronic
immune thrombocytopenic purpura. Hematology. 2009 Aug; 14(4): 227-36.
-
Lech-Maranda E, Seweryn M, Giebel S, Holowiecki
J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K,
Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B,
Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko
J, Warzocha K, Robak T. Infectious complications in patients with acute myeloid
leukemia treated according to the protocol with daunorubicin and cytarabine
with or without addition of cladribine.A multicenter study by the Polish Adult
Leukemia Group (PALG). Int J Infect Dis. 2010 Feb; 14(2): e132-40.
Epub 2009 Jul 5.
-
Peruga J, Plewka M, Kasprzak J, Jezewski T,
Wierzbicka A, Robak T, Krzemińska-Pakuła M. Intracoronary administration of
stem cells in patients with acute myocardial infarction -
angiographic follow-up. Kardiol Pol. 2009 May; 67(5): 477-84.
-
Lech-Maranda E, Korycka A, Robak T. Clofarabine
as a novel nucleoside analogue approved to treat patients with haematological
malignancies: mechanism of action and clinical activity. Mini Rev Med Chem.
2009 Jun; 9(7): 805-12.
Review.
-
Robak T. Novel drugs for chronic lymphoid
leukemias: mechanism of action and therapeutic activity. Curr Med Chem. 2009; 16(18): 2212-34.
Review.
-
Robak T. GA-101, a third-generation, humanized
and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Curr Opin Investig Drugs. 2009 Jun; 10(6): 588-96.
-
Harousseau JL, Martinelli G, Jedrzejczak WW,
Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G,
Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva
NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes
AJ; FIGHT-AML-301 Investigators. A randomized phase 3 study of tipifarnib
compared with best supportive care, including hydroxyurea, in the treatment of
newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood.
2009 Aug 6; 114(6): 1166-73.
-
Giebel S, Holowiecki J, Krawczyk-Kulis M, Jagoda
K, Stella-Holowiecka B, Sadus-Wojciechowska M, Hellmann A, Dmoszynska A,
Paluszewska M, Robak T, Konopka L, Seferynska I, Skotnicki AB, Kyrcz-Krzemien
S. Impact of granulocyte colony stimulating factor administered during
induction and consolidation of adults withacute lymphoblastic leukemia on
survival: long-term follow-up of the Polish adultleukemia group 4-96 study.
Leuk Lymphoma. 2009 Jun; 50(6): 1050-3.
-
Wolska A, Lech-Maranda E, Robak T. Toll-like
receptors and their role in hematologic malignancies. Curr Mol Med. 2009 Apr; 9(3): 324-35.